Psoriasis Clinical Trial

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Summary

This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

View Full Description

Full Description

This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female ≥18 years of age at clinic visit.
Documentation of moderate-severe psoriasis or atypical psoriasis.
Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
Tuberculosis, active serious infection, active systemic malignancy,
Received a systemic medication for psoriasis within 3 months of study screening

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

7

Study ID:

NCT04541329

Recruitment Status:

Completed

Sponsor:

University of California, San Francisco

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of California, San Francisco
San Francisco California, 94158, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

7

Study ID:

NCT04541329

Recruitment Status:

Completed

Sponsor:


University of California, San Francisco

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.